Internal Medicine, Endocrinology, Diabetes, & Metabolism · Edinburg, TX
NPI
1811284078
Since 2011
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2609 Michaelangelo Dr
Edinburg, TX, 78539
Phone (956) 362-5650
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
418 services
Medicare patients, 2024
220
Average age 69
Drug cost, 2024
$6.9M
14,168 prescriptions
Company payments, 2025
$362
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Juan D Palacios Merchan was code 99214 (office e&m - established), 222 times for 125 patients. In total Juan D Palacios Merchan billed 418 services in 8 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 222 | 125 | $63.78 | $14K |
| 99214 Office E&M - Established | Office | 129 | 79 | $88.11 | $11K |
| 99204 Office E&M - New | Facility | 19 | 19 | $81.39 | $1,546 |
| 95251 Test - Miscellaneous | Facility | 14 | 11 | $24.00 | $336 |
| 99204 Office E&M - New | Office | 13 | 13 | $105.40 | $1,370 |
By year: 2022 $38K for 515 services; 2023 $39K for 545 services; 2024 $30K for 418 services.
Medicare prescription drug claims, 2024
In 2024, the drug Juan D Palacios Merchan prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,382 prescriptions and refills. In total Juan D Palacios Merchan wrote 14,168 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,382 | 1,923 | 268 | $1.8M |
| Levothyroxine Sodium Generic | 1,086 | 2,940 | 332 | $12K |
| Glipizide Er Glipizide | 1,024 | 2,641 | 306 | $20K |
| Atorvastatin Calcium Generic | 829 | 2,121 | 283 | $7,873 |
| Jardiance Empagliflozin | 720 | 1,313 | 176 | $745K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 477 | 974 | 127 | $545K |
| Rosuvastatin Calcium Generic | 474 | 1,183 | 171 | $6,784 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 402 | 885 | 160 | $46K |
| Trulicity Dulaglutide | 389 | 636 | 105 | $606K |
| Tresiba Flextouch U-100 Insulin Degludec | 375 | 806 | 119 | $314K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 302 | 672 | 97 | $44K |
| Pioglitazone Hcl Generic | 301 | 829 | 97 | $4,094 |
| Metformin Hcl Generic | 296 | 734 | 94 | $2,373 |
| Novolog Flexpen Insulin Aspart | 274 | 440 | 77 | $71K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 243 | 389 | 76 | $18K |
Brand drugs: 7,047 claims; generic drugs: 6,029 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Juan D Palacios Merchan $362 ($362 in general payments such as food, travel and fees) from 4 companies. The largest payer was Neurocrine BioSciences, Inc. with $138.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.